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Abstract
The microbes colonizing the infant gastrointestinal tract have been implicated in later-life disease states such as
allergies and obesity. Recently, the medical research community has begun to realize that very early colonization
events may be most impactful on future health, with the presence of key taxa required for proper immune and
metabolic development. However, most studies to date have focused on bacterial colonization events and have left
out fungi, a clinically important sub-population of the microbiota. A number of recent findings indicate the
importance of host-associated fungi (the mycobiota) in adult and infant disease states, including acute infections,
allergies, and metabolism, making characterization of early human mycobiota an important frontier of medical
research. This review summarizes the current state of knowledge with a focus on factors influencing infant
mycobiota development and associations between early fungal exposures and health outcomes. We also propose
next steps for infant fungal mycobiome research, including longitudinal studies of mother–infant pairs while
monitoring long-term health outcomes, further exploration of bacterium–fungus interactions, and improved
methods and databases for mycobiome quantitation.
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Background
The beneficial role of microbial colonization to human
health is becoming increasingly clear. Recent efforts to
define a healthy microbiota show that the microbial
communities inhabiting our bodies are diverse and
complex, and that colonization dynamics during early life
may have lasting impacts on adult health [1]. The term
“microbiome” describes the community of microbes living
on and within an organism using genetic analysis, usually
within a particular niche or body site. Most literature
discussing the microbiome, however, pertains only to the
bacterial microbiota. Although bacteria constitute the
majority of the non-host biomass of humans, they are not
the only microorganisms contributing to the microbial
ecosystem of the host. For example, human-associated
fungi have been largely overlooked. On a cellular basis, ap-
proximately 0.1% of the microbes in the adult intestine are
fungi, and these fungi are estimated to represent approxi-
mately 60 unique species [2, 3]. Although fungi can be
human pathogens, especially in association with under-
lying immunodeficiencies, many fungi are benign com-
mensal inhabitants of human body niches and some have
been shown to confer health benefits. For example,
previous culture-based and targeted PCR approaches for
characterizing the mycobiota have shown humans to be
colonized with commensal fungi across multiple body
sites [4, 5]. Some species, such as Saccharomyces boular-
dii, have been shown to be effective at preventing and
treating human gastrointestinal (GI) diseases (e.g.,
diarrhea, inflammatory bowel disease, irritable bowel syn-
drome) [6, 7]. Importantly, overgrowth of fungi leading to
infections is more common in infants than adults and can
result in significant morbidity and mortality in at-risk
infants such as those born prematurely [8–10]. Thus,
knowing what a healthy fungal microbiota (mycobiota) is
composed of and what factors affect its establishment and
maturation during infancy is important if we are to learn
how early-life microbial communities affect pediatric and
adult health.
With the advent of next-generation sequencing and
introduction of low-cost bacterial community profiling
approaches, such as 16S rDNA amplicon sequencing,
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bacterial microbiomes can now be more easily and
quickly characterized than ever before. In contrast, de-
velopment of robust methods to characterize human-
associated mycobiota has lagged behind that for bacterial
community characterization due to difficulties in
sequencing low human-associated fungal biomass and
fungal cultivation issues preventing reference sequence
generation [11, 12]. Until recently, the majority of
published fungal microbiota analyses have relied upon
culturing fungi, a method that is less sensitive than
sequencing-based approaches [11, 12]. Because fungi are
much less abundant than bacteria in most, if not all,
human niches, a shotgun metagenomic sequencing ap-
proach for the characterization of fungal communities
has not been productive. As such, PCR amplicon-based
sequencing approaches have been developed and con-
tinue to be refined for mycobiome analyses. Genomic
targets that have been utilized include the 18S and 28S
rDNA sequences, and the internal transcribed spacer re-
gions (ITS1 and ITS2) of the rDNA locus [12]. The ITS
regions of the fungal genome are highly variable and
capable of providing identification at the species level,
but taxonomic characterization of fungi remains challen-
ging as the reference databases available for fungi are far
from comprehensive, with up to 20% of sequences anno-
tated incorrectly [13]. Thus, mycobiome characterization
may be biased by the marker gene region sequenced and
the reference database used. Until improved reference da-
tabases are available and new marker gene sequences that
more universally distinguish fungi are identified, methods
combining broad DNA amplicon surveys with a targeted
approach, such as quantitative PCR and/or culturing, will
likely be needed to gain robust and accurate mycobiome
characterization [14]. Given these challenges, throughout
this review we note the particular approach employed by
each study to characterize mycobiota.
Herein, we focus on the current state of mycobiota re-
search in infants, including culture-based, targeted and
broad survey-based genomic approaches, with a focus
on two aspects of infant mycobiota research, namely fac-
tors influencing early-life mycobiota and potential links
between early fungal exposures and health outcomes.
Because research on the mycobiota of infants is limited,
we consider the current state of fungal knowledge in the
context of factors known to influence infant-associated
bacterial microbiota, including mode of delivery, mater-
nal mycobiota, feeding composition, environmental ex-
posures (e.g., antibiotics), and gestational age at delivery
[15–17]. Our findings are summarized in Figs. 1 and 2.
Factors affecting infant mycobiota
Birth mode
Whether an infant is born vaginally or through caesarean
delivery (C-section) most drastically affects the composition
Fig. 1 The mycobiome of infants is influenced by the mother’s mycobiome and other factors. Fungal genera associated with healthy
adults (a) and infants (b). Body sites with an asterisk represent those that have only been characterized by culture or targeted PCR
approaches; broad mycobiome surveys are lacking for these sites. Genera noted in bold type represent the dominant genus reported for that body
site, as determined by broad mycobiome survey. Taxa listed are derived from targeted studies and broad survey approaches (≥1% of mycobiome)
[2, 5, 14, 22–26, 28–39, 47, 51–54]. Also depicted are the major factors thought to influence the infant mycobiome
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of their associated bacterial communities over the first
6 months of life [18–21]. For example, in a study of 98
mother–infant pairs, vaginally-born infants had less fecal
Enterobacter, Haemophilus, Staphylococcus, Streptococcus,
and Veillonella species and had increased Bacteroides,
Bifidobacterium, Parabacteroides, and Escherichia compared
to infants born by C-section [20]. In this same study, vertical
transmission of the mother’s fecal microbiota was likely the
most significant contributor to the difference between
vaginally and C-section-born infants, as 72% of bacteria
colonizing feces of vaginally-born infants were present in
their mother’s fecal microbiome, as compared to only 41%
for C-section-born infants.
Vertical transmission of fungi from mother to infant has
been most extensively studied with regard to the fungal
species Candida albicans. In a study of very low birth-
weight infants, 24% of infants (n = 46) were colonized at a
minimum of one site (oral cavity, rectum or groin) with C.
albicans within 1 week of birth by the same C. albicans
isolate present in either their mother’s vagina, rectum, skin
or mouth, as determined by culturing and DNA finger-
printing (Fig. 1) [22]. Given this example of vertical trans-
mission of one fungal taxon, it is likely that other
members of the maternal vaginal mycobiota are also
transferred to the infant. Therefore, by better understand-
ing fungi that inhabit the birth canal of the mother, we
may gain insight into which fungal taxa may be trans-
ferred to the infant.
Historically, studies have focused on the characterization
of one fungal genus within the female genital tract, Candida,
due to its importance as a cause of infection (vaginitis). In a
study of Candida colonization of the vagina of asymptom-
atic women without a history of vaginal candidiasis, 28.8%
of women were positive for C. albicans by targeted PCR
analysis, demonstrating that Candida is a normal com-
mensal of the female genital tract (Fig. 1). Of note, only 6.6%
of these women were positive for Candida by culture,
highlighting the limitations of fungal community analysis
using culture-based approaches [5]. In another screen of
asymptomatic women without a history of vaginal candidia-
sis, 40% (n= 52) of the sampled individuals carried at least
one isolate of Candida (~90% of which were C. albicans) in
their genital tracts (vulva or vagina), as determined by DNA
fingerprinting of cultured Candida [23]. To our knowledge,
there has only been one published broad survey of the vagi-
nal mycobiome using the ITS region [24]; in this survey of
Fig. 2 Factors influencing the infant mycobiome and mycobiome-associated health outcomes. Mode of delivery, mother’s microbiota, diet, gestational
age at birth, and antibiotic exposure can influence the infant mycobiome. These factors can also impact the infant bacterial microbiome, which in turn
shapes the mycobiome. The mycobiome has been noted as a source of fungal overgrowth [65–67], can modulate the bacterial microbiome [70], is
implicated in inflammatory bowel disease [88–92], and has been associated with obesity [29, 76–80]. Exposure to fungi has been implicated in allergic
disease development [82, 93] and beneficial fungi, such as Saccharomyces boulardii, can be used to alleviate pediatric diarrhea [84–86, 93]
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healthy women (n = 251), Candida was the predominant
genus and was present in 68% of samples, followed by
Davidiella, Cladosporium and other less abundant fungi
(Fig. 1). Of note, a large number of sequences in this study
were not classified into a fungal taxonomic group, likely due
to the under-representation of fungal sequences in currently
available databases, as well as inconsistencies in the taxo-
nomic classification of fungi. Nevertheless, the vaginal
mycobiota likely plays an important role in the early
colonization events of vaginally born infants.
Apart from C. albicans, mother–infant transmission
has not been well studied for fungi. In a recent survey of
four infants and their mothers using universal 18S rDNA
primers [25], no amplicon was produced from DNA iso-
lated from infant fecal samples at any time point,
whereas the same samples were able to produce ampli-
cons using universal 16S primers for bacteria. Fecal
DNA from the mothers in this study produced 18S
amplicons corresponding to Blastocystis (a parasite of
the Stramenopile group), Saccharomyces, Candida,
Nicotiana, and Cicer, among other fungal genera, leading
the authors to conclude that the infant fecal samples
contained no fungi. In contrast, in a study of very low
birth weight infants, ITS2 amplicons were produced
from the feces of the majority of infant samples (7 of 11)
with the predominant genus being Saccharomyces (S.
cerevisiae) followed by Candida (C. albicans, C. glab-
rata, C. quercitrusa, C. diddensiae, C. parapsilosis, and
C. tropicalis), Cladosporium (C. sphaerospermum and C.
tenuissimum), and Cryptococcus (C. albidosimilas and C.
podzolicus) [26]. Similarly, in a study of 11 infant fecal sam-
ples using fungal-specific PCR along with ITS2-based se-
quence analysis, fungi were observed in all samples, with C.
albicans being the predominant species followed by C.
parapsilosis, C. krusei, and Leptosphaerulina [14]. Penicil-
lium, Aspergillus, Candida, Debaryomyces, Malassezia,
Ascomycota, Eurotiomycetes, Tremellomycetes, Nectriaceae,
and Trichosporon were also observed in an ITS1 survey of
infants under 2 years of age, and the presence of many spe-
cific taxa was confirmed by culture-based methods [27]. A
longitudinal study of 14 infants also showed fungi to be
present in the feces of all infants, at most time points, at a
density of 104–106 rRNA genes/g of feces over the first
200 days of life [28]. This is in contrast to the 109–1010 bac-
terial rRNA genes/g of feces reported for the same samples
[28]. Despite one study reporting a lack of fungi in the infant
GI tract, we conclude that most infants do harbor GI fungi
(Fig. 1). Although fecal fungal RNA appears to be less abun-
dant than bacterial RNA, fungal cells are considerably larger
(100-fold) than bacterial cells. Thus, fungi contribute a sub-
stantial biomass to the fecal microbiota.
The extent of transfer of fungal communities from
mother to infant remains unclear, but the overlap of the
infant and the adult GI mycobiome does support the
hypothesis of vertical mycobiota transmission. For example,
in adults, fungi were detected in all fecal samples of 96 indi-
viduals by ITS sequencing, and the most abundant genera
were Saccharomyces, Candida, and Cladosporium [2]. Simi-
larly, in healthy controls (n = 12) from an ITS sequence-
based survey of obese and lean individuals [29], Mucor,
Candida, Penicillium, Wallemia, Bettsia, and Cladoporium
were the predominant genera in feces, along with more
minor members, and the healthy controls (n= 55) from a
study of hepatitis-infected individuals were colonized with
Saccharomyces, Candida, Aspergillus, Malassezia, Penicil-
lium, and an uncharacterized fungus, as determined by 18S
restriction fragment length polymorphism (RFLP) analysis
[30]. The adult GI mycobiome, as characterized by ITS1
sequencing, has also been shown to contain Candida,
Penicillium, Aspergillus, Malassezia, Debaryomyces, Mucor,
Eremothecium, Pichia, and Cyberlindnera (healthy controls,
n = 29) [31]. Further, Saccharomyces and Penicillium species
were also detected by denaturing gradient gel electrophor-
esis and 18S rDNA sequence analysis of fecal samples from
healthy adults, along with other fungal genera [32], and
Candida species predominated in a study of 45 adult fecal
samples using ITS sequencing [33]. In the latter study, only
two fungal taxa were shared in a majority of samples, indi-
cating an absence of core GI tract mycobiota [33]. Addition-
ally, the observation of instability across longitudinal
samples in the study further indicated the lack of a core
mycobiota, although further testing with a larger sample size
should be performed to confirm this hypothesis [33]. The
fungal taxa shared across the infant and adult studies in-
clude Candida, Saccharomyces, and Cladosporium, but
given the limited number of studies in infants and their
small sample sizes, there are likely more fungal taxa that
overlap between the two groups (Fig. 1). The observation of
shared taxa between adults and infants provides support for
the hypothesis of vertical transmission of GI mycobiota
from mother to infant.
In C-section born infants, the bacterial microbiota of
the skin and GI tract are more similar to those of the
mother’s skin [21]. If this also holds true for the myco-
biome, the skin and GI tract mycobiomes of C-section
born infants would be expected to be dominated by
Malassezia [34]. In a longitudinal study of infants that
investigated skin colonization with Malassezia by
Malassezia-specific PCR, two species (M. restricta and
M. globosa, also observed on adult skin) were detected
on the infant skin as early as the first day of life (89%),
and abundance levels increased to that observed in
adults by day 30 of life (Fig. 1) [35]. In addition, in the
same study, vertical transmission of Malassezia from the
skin of mothers to that of infants was confirmed by
genotyping of the intergenic spacer region located
downstream of the ITS1 and 2 regions. The targeted
approach used in this study, however, prevents us from
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determining the proportion of Malassezia relative to other
mycobiome members, warranting further exploration of
the infant skin mycobiota with broad survey approaches.
To better understand the infant skin mycobiota as a
community, we can consider adult studies that employ
culture-dependent and independent methods. For
example, in a study of ITS1 sequences from 14 skin sites
of 10 healthy adults, the skin mycobiome, with the
exception of the feet, was dominated by the genus
Malassezia [34], consistent with the findings of other
studies using culture and targeted PCR approaches
[34–39]. Other members of the skin mycobiome, found
either on a small number of people or in low abundance,
included Candida, Rhodotorula, Saccharomyces, and
Penicillium, along with several much less abundant fungi
[34, 37]. For studies using ITS1 sequencing, however, it
should be noted that such sequences are somewhat biased
toward identification of basidiomycetous fungi, such as
Malassezia, whereas ITS2 sequences favor identification
of ascomycetous fungi such as most other human-
associated fungi, including Candida [40]. Thus, it is
possible that the ITS1-based approach used in the study
by Findley et al. [34] was not sensitive enough to fully de-
tect Ascomycetes present in the samples. Nevertheless,
the vertical transmission ofMalassezia from mother to in-
fant further supports the hypothesis that birth mode im-
pacts the mycobiota of the infant. Based on the studies
mentioned above, we can hypothesize that infants born
vaginally would have a higher proportion of Candida in
their mycobiome given the Candida-predominated birth
canal, and potentially have a more diverse mycobiome in
comparison to those born by C-section given the exposure
to the mother’s varied fecal mycobiota. Conversely, we can
hypothesize that C-section infants, whose colonization
source is often the mother’s skin, would be colonized by
relatively higher amounts ofMalassezia (Fig. 2).
Diet
Diet composition, such as human milk or formula,
strongly affects early infant bacterial microbiomes within
the GI tract as well as in later infancy during the transition
to solid foods [20, 41]. For example, breast-fed infants har-
bor more Bifidobacteria and Labctobacilli in their GI
tracts in comparison to formula-fed infants [20, 28], likely
due to the endogenous microbiome of human milk and
human milk factors, such as oligosaccharides and immune
proteins, that modulate the growth of certain bacteria. In
several studies, many bacterial genera found in human
milk (Bifidobacterium, Bacteroides, Staphylococcus,
Streptococcus, Pseudomonas, Lactobacillus, and others)
were also found in infant fecal samples [42–44]. Addition-
ally, prebiotics in breast milk, such as human milk
oligosaccharides, promote the preferential expansion of
certain taxa such as Bifidobacterium species [45, 46].
Although the human milk mycobiome has yet to be char-
acterized, we know that some fungi, such as Candida
species, are found in milk from mothers with mammary
candidiasis (67.4%, n = 46) as well as in asymptomatic
controls (79.1%, n = 43) (Fig. 1) [47]. Human milk oligo-
saccharides have also been demonstrated to impact fungal
virulence in vitro by decreasing the ability of C. albicans
to invade intestinal epithelial cells [48]. Thus, it is rational
to hypothesize that human milk also influences the infant
GI mycobiota, although this remains to be tested.
Diet also affects the oral bacterial microbiota of infants
[49], and this likely holds true for the mycobiota. In in-
fants, oral colonization with fungi has only been studied
using culture-dependent methods, with Candida species
appearing to be the predominant fungi, although this
finding may be biased because these species grow most
easily on certain growth media. In one study of 100
healthy infants, 12% were orally colonized with Candida
by 4 weeks of age and colonization prevalence rates did
not change over the first 6 months of life [50]. Other
studies also show oral Candida colonization rates to be
low at birth, but to rise over time to adult carriage rates
within the first year of life [51, 52]. The species of Can-
dida currently reported as commensals of the oral cavity
of infants include C. albicans, C. parapsilosis, C. krusei, C.
guillermondii, C. geocandidum, and C. tropicalis [51, 52].
In adults, the oral mycobiota is reportedly diverse. For ex-
ample, in one study using ITS2 sequencing to characterize
oral mycobiomes, healthy individuals (n = 20) had a range
of 9 to 23 fungal species within the oral cavity at a given
time; the ‘core’ members of the oral community included
Candida, Cladosporium, Aspergillus, Fusarium, Glomus,
Penicillium, Alternaria, Cryptococcus, Ophiosoma, Phoma,
Schizosaccharomyces, Zygosaccharomyces, and Saccharo-
myces [53]. Another study of adult saliva samples (n = 3)
reported Malassezia as the dominant taxon, in addition to
more minor mycobiome members such as Epicoccum or
Irpex and others previously reported [54]. Therefore, given
the diversity of the adult oral mycobiome, we can
hypothesize that the oral mycobiome of infants likely con-
tains other taxa in addition to Candida, and that the oral
mycobiome of infants is likely dynamic, with changes es-
pecially noticeable as the infant transitions to a more
adult-like diet (Fig. 2).
Gestational age at delivery
Gestational age at delivery has been shown to impact
the bacterial microbiota, including initial community dif-
ferences and the pace of bacterial community matur-
ation, but differences are often resolved by 2 years of
age, when the bacterial community has reached an
adult-like state [55–57]. For infants born at an early
gestational age, the health impact of intestinal fungi is
particularly significant, as the incidence of invasive,
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systemic candidiasis in these infants is approximately
10%, with an associated mortality rate of approximately
20% [58]. Susceptibility to invasive infection has been
correlated with relative overgrowth of fungi, especially
within the GI tract [8–10], as well as the presence of
several predisposing clinical factors including a naïve
immune system, bacterial dysbiosis due to antibiotic
exposure, and use of parenteral nutrition, among other
factors (Fig. 2) [59]. In an attempt to reduce rates of in-
vasive candidiasis in this vulnerable population, prophy-
lactic antifungals, such as nystatin and fluconazole, are
often used in neonatal intensive care units. In particular,
fluconazole has been shown to reduce Candida over-
growth at several body sites, including skin, the respiratory
tract, and the GI tract, and its use has been associated
with a decreased rate of invasive candidiasis in extremely
low birth weight infants [60, 61]. Recently, the enteral ad-
ministration of bacterial and fungal probiotics, such as
Lactobacillus reuteri, L. casei, L. rhamnosus, L. acidoph-
ilus, Streptococcus thermophilus, Bidiobacterium longum,
B. bifidum, B. lactis, and S. boulardii, have also been used
to reduce invasive candidiasis [59, 60]; however, their effi-
cacy remains unclear and their primary site of action is
limited to the GI tract. Despite the administration of anti-
fungals, fungal colonization still occurs in some infants, as
demonstrated in a study of 11 extremely low birth weight
infants, all of whom received an enteral anti-fungal treat-
ment, nystatin, as well as antibacterial antibiotics [26]. Of
these 11 infants, 7 produced ITS amplicons from their
stool, with Saccharomycetales being the most abundant
order, as well as Candida and Cryptococcus species. Thus,
despite efforts to prevent fungal colonization, fungi main-
tain the ability to persist in the infant GI tract. In infants
born at early gestational ages, beneficial fungi, such as S.
boulardii, may help to regulate the growth of opportunis-
tic fungal colonizers such as Candida. Additionally, given
the association of bacterial dysbiosis with systemic candid-
iasis in infants born at an early gestational age, a robust
bacterial community may play an important role in myco-
biota regulation, as discussed below.
Infant mycobiota health associations
Antibiotic exposure and fungal overgrowth
The bacterial community of infants is significantly altered
by exposure to antibiotics in both term and preterm in-
fants [16, 62, 63]. For example, in a longitudinal study over
the first 3 years of life, infants receiving multiple courses
of antibiotics had immediate bacterial community changes
following antibiotics and an overall less diverse fecal bac-
terial microbiome than those not given antibiotics [64].
Although most commonly used antibiotics do not directly
act on fungi, anti-bacterial antibiotic exposure is associ-
ated with alterations to the mycobiota, such as increased
rates of fungal colonization, fungal overgrowth, and
changes in fungal community structure, as tested in mice
[65]. In premature infants, exposure to third generation
(broad-spectrum) cephalosporins is highly associated with
an increased risk for both mucosal and invasive candidia-
sis [66], and in women, antibiotic exposure is associated
with an increased incidence of fungal infections of the
genitorurinary tract (Fig. 2) [67]. Recent studies have also
reported that susceptibility to fungal overgrowth is pri-
marily due to changes in the bacterial community follow-
ing antibiotic exposure rather than immune status of the
GI tract or the presence of specific fungal taxa [68, 69].
The proposed mechanisms of fungal colonization regula-
tion by bacteria include physical restriction, resource
competition and the production of anti-fungal molecules
[68, 69]. Without these mechanisms of regulation, oppor-
tunistic fungi, such as Candida, can outgrow their occu-
pied niche and initiate immune responses or cause acute
infections, especially in immunocompromised individuals
including premature infants.
The converse relationship that fungi affect bacterial
colonization is also true, as recent animal experiments
showed C. albicans colonization of the GI tract to be as-
sociated with altered bacterial repopulation following
cefoperazone treatment, including increased Entero-
coccus faecalis levels and a lack of Lactobacillus recovery
[70]. Specific bacterial and fungal taxa have also been
shown to co-occur outside the scope of antimicrobial ex-
posure. For example, in a study of stools from healthy
adults, Candida was positively correlated with the
presence of Prevotella, Ruminococcus, and Methanobre-
vibacter [2]. On adult skin, Malassezia was positively
correlated with Corynebacterium, Prevotella, and Propi-
onibacterium and negatively correlated with Pseudo-
monas, Acinetobacter, Streptococcus, and Enhydrobacter
[71]. Additionally, certain fungal taxa are reported to
regulate the growth of other fungi through the produc-
tion of anti-fungal molecules. For example, the adult oral
taxon, Pichia, is negatively correlated with the predom-
inant oral taxon Candida and Pichia-produced factors
isolated from growth media were able to prevent growth
of Candida, Fusarium, and Aspergillus both in vitro and
in mice [72]. Therefore, the fungal community is dy-
namic, self-regulating, and interacts with the bacterial
community. Thus, future studies should include the ana-
lysis of both the bacterial and fungal components of the
community in observational studies, as well as during
experimental interventions (Fig. 2).
Obesity
In adults and children, obesity is associated with altered
bacterial microbiota and, in infants, administration of
antibiotics (known modulators of the bacterial commu-
nity) is also associated with obesity later in life [73–75].
Similarly, fecal mycobiomes of obese and lean adults are
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reported to differ, with the genera Mucor and Penicil-
lium negatively correlating with increased measures of
adiposity and weight gain, and the genus Aspergillus
positively correlating with increased measures of adipos-
ity and weight gain [29]. In children, obesity has been
associated with lower abundances of Candida and
Saccharomyces species, as analyzed by DNA fingerprint-
ing and quantitative PCR [76]. However, the role of early
fungal colonization of infants and obesity outcomes has
not yet been studied. We hypothesize that, similar to
bacteria, some early-life fungi will be beneficial and
some detrimental to short- and long-term metabolic
health. For example, administration of S. boulardii and
fungal-specific molecules (β-glucan) to humans and ani-
mals have been shown to reduce obesity-related pheno-
types [77–80]. Therefore, direct manipulation of obesity-
related fungal taxa in early life should be explored as a
potential preventative strategy against obesity.
Allergic disease
Based on animal models and associations in humans,
there are bacterial taxa that are associated with protec-
tion against allergic diseases later in life. For example, in
a study of 319 infants, GI colonization with Faecalibac-
terium, Lachnospira, Veillonella, and Rothia was
associated with a decreased risk of asthma and these
same taxa were able to prevent airway inflammation in
mice when used to colonize their GI tracts [81].
Whether there are key early-life fungal taxa that prevent
allergic disease development remains unknown. How-
ever, a role for fungi in both allergy development and
prevention was suggested by a study of 144 infants in
whom exposure to airborne fungal spores from Penicil-
lium/Aspergillus and Alternaria were positively associ-
ated with positive skin-prick tests for at least one
allergen within a general allergy panel, whereas Clados-
porium exposure was negatively associated with allergy
development (Fig. 2). In addition, exposure to increased
levels of environmental (bedroom) fungi during infancy
were found to be negatively associated with later-
childhood development of wheeze and asthma, whereas
increased indoor Aspergillus and outdoor Cladosporium
levels were positively associated with a later increased
incidence of rhinitis [82]. Thus, although the specific
taxa and clinical outcomes involved need further explor-
ation, there is strong evidence that early life exposure to
certain fungal taxa contribute to allergic disease (Fig. 2).
Pediatric diarrhea
Diarrheal diseases are a significant cause of morbidity
and mortality, accounting for approximately 760,000
deaths per year in children under the age of 5 [83]. The
causes of diarrhea are varied, including antibiotic-
associated and infectious diarrhea, amongst others. S.
boulardii has been evaluated as a treatment and pre-
ventative strategy for many types of diarrhea, with
mostly positive outcomes [84, 85]. For example, a meta-
analysis of five clinical trials reported that S. boulardii is
effective in preventing antibiotic-associated diarrhea in
adults and children [86], and a separate meta-analysis
also reported S. boulardii to be effective at reducing the
duration of diarrhea in children with acute infectious
gastroenteritis [87]. A third meta-analysis including 22
studies further concluded that S. boulardii can signifi-
cantly reduce the duration of childhood diarrhea,
whether caused by bacteria, viruses, or protozoa [85].
The mechanism whereby S. boulardii alleviates diarrhea
is not yet clear, but animal models and in vitro work
have shown S. boulardii to possess antimicrobial activ-
ities, inhibit bacterial toxins, promote barrier function of
the intestinal epithelium, and elicit specific immune re-
sponses by the host [84]. Whether early exposure to S.
boulardii is beneficial for the long-term health outcomes
of infants remains to be tested, but the beneficial effect
of S. boulardii on pediatric diarrhea is clear.
Inflammatory bowel disease (IBD)
The dysbiotic microbial communities associated with
IBD are becoming more defined, including fungi associ-
ated with disease development. In pediatric patients
(aged 3–21 years), there is a clear IBD-associated fungal
signature as analyzed by ITS1 sequencing, including in-
creased relative abundances of Pichia jadinii and
Candida parapsilosis and a decreased relative abundance
of Cladosporium cladosporiodes (n = 32), as well as an
overall decrease in fungal diversity within the stool of
IBD patients as compared to controls (n = 90) [88]. An
additional study also found pediatric IBD patients to
have a fungal community different than healthy controls,
including a predominance of Basidiomycota, although
only a small portion of colonic biopsies yielded fungal
amplicons (8 of 37 samples) [89]. These results are sup-
ported by ITS2 sequence analysis in a survey of adults
with IBD that demonstrated an increased Basidiomyco-
biota/Ascomycota ratio, as well as an increased relative
abundance of Candida albicans and decreased relative
abundance of Saccharomyces cerevisiae in IBD patients
(n = 235) as compared to controls (n = 38) [90]. While
distinct gut fungal community structures are associated
with IBD, it remains unclear as to whether microbial ex-
posure or early colonization contributes to disease devel-
opment. In a mouse model of chemically-induced colitis,
fungi associated with IBD were capable of intestinal in-
vasion only in animals deficient for the fungal pattern
recognition receptor dectin-1 and not in wild-type
animals. This suggests a causative role of host genetics,
rather than a specific microbial community signature, in
IBD [91]. Nevertheless, the fungal community appeared
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to contribute to disease severity, and future work regard-
ing host-fungi interactions in early-life are needed to
better understand IBD development and progression.
Conclusion and future directions
Although there is a relatively small number of broad
mycobiome surveys for infants, by considering them in
aggregate we can begin to answer certain important bio-
logical questions regarding early-life mycobiota develop-
ment. For example, the use of targeted studies has shown
the vertical transmission of specific fungal taxa, such and
Candida and Malassezia, from mother to infant [22, 35],
and this type of mycobiota inheritance is worth exploring
for all mycobiome members. Additionally, broad surveys of
infant feces have captured snapshots of the dynamic fungal
community in early life, and have begun to shed light on
other fungal taxa inhabiting infants [14, 25, 26, 28]. The di-
versity and disease associations of adult mycobiota also pro-
vide further motivation to characterize infant mycobiota
throughout development.
Future studies should focus on longitudinal tracking of
the early-life mycobiota using mother–infant pairs while
monitoring health outcomes, such as obesity, allergic
disease, and acute fungal infections, well past the first
year of life. The data generated from such studies would
elucidate the impact of the mother’s mycobiota, and
other environmental factors, on the infant mycobiota,
and would document temporal changes of the myco-
biome throughout development. Additionally, given the
known interactions between the bacteria and fungi, fu-
ture studies should include the analysis of both bacteria
and fungi to better characterize their structural and
functional relationships, as well as their combined ef-
fects on health outcomes. Furthermore, more research is
needed to address the methodological challenges in gen-
erating fungal microbiome data, including sampling of
low fungal biomass, generation of comprehensive and
reliable reference databases, and improvement of in-
formatics methods tailored to classifying fungal
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